Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL–RANK interaction
Abstract
It is well known that thyroid hormone excess causes bone loss. However, the precise mechanism of bone loss by thyroid hormone still remains unclear. When T 3 was added to unfractionated bone cells after degeneration of pre‐existent osteoclasts, T 3(1 pM–100 nM) dose‐dependently stimulated osteoclast‐like cell formation, irrespective of the presence of indomethacin and IL‐6 Ab. T 3 increased the expression of osteoprotegerin (OPG) messenger RNA (mRNA), but not of receptor activator of nuclear factor κB ligand (RANKL) in unfractionated bone cells, suggesting that the stimulatory effect of T 3 on osteoclast formation was not mediated by the RANKL/OPG system. We next examined the direct effect of T 3 on osteoclast precursors in the absence of osteoblasts, using hemopoietic blast cells derived from spleen cells. T 3(1 pM–100 nM) dose‐dependently stimulated osteoclast‐like cell formation from osteoclast precursors. OPG did not inhibit T 3‐induced osteoclast formation from osteoclast precursor cells. The polymerase chain reaction (PCR) product corresponding in size to the mouse T 3 receptor α1 cDNA was detected in osteoclast precursors from mouse hemopoietic blast cells as well as mouse heart and mouse osteoblastic cell line MC3T3‐E1 cells, suggesting that T 3 directly stimulated osteoclast‐like cell formation from osteoclast precursors in the absence of osteoblasts. Further, T 3 increased the expression of c‐Fos mRNA at 15 min and 24 h and Fra‐1 mRNA at 2 and 6 h in osteoclast precursors. Consistent with the increased expression of c‐Fos mRNA observed by RT‐PCR, the activation of c‐Fos occurred in osteoclast precursor cells stimulated by T 3, while the activation of neither NF‐κB nor MAPKs was observed by immunoblot analysis. Antisense oligodeoxynucleotides (as‐ODN) complementary to c‐Fos mRNA at 1 μM significantly inhibited T 3‐induced osteoclast‐like cell formation from osteoclast precursors in the absence of stromal cells while sense‐ODN did not affect T 3‐induced osteoclast‐like cell formation. These results indicate that T 3 directly stimulates osteoclast differentiation at least in part by up‐regulation of c‐fos protein in osteoclast precursor cells. J. Cell. Physiol. 201: 17–25, 2004. © 2004 Wiley‐Liss, Inc.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Thyroid hormone indirectly promotes osteoclast formation and activation by inducing the expression of cytokines, prostaglandins and the receptor activator of nuclear factor NF-kB ligand.
“Thyroid hormone indirectly promotes osteoclast formation and activation by inducing the expression of cytokines, prostaglandins and the receptor activator of nuclear factor NF-kB ligand [12, 36, 37].”
From Effects of levothyroxine therapy on bone and mineral metabolism in hypothyroidism: a systematic review and meta-analysis (2025) · cites this paper as [36]
Cites
Risk Factors for Hip Fracture in White Women
Cummings, S. R., Nevitt, M. C., Browner, W. S., Stone, K., Fox, K. M., Ensrud, K. E., Cauley, J., Black, D., & Vogt, T. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503233321202 · Cited by 3,595 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Role of Thyroid Hormones in Skeletal Development and Bone Maintenance
Bassett, J. H. D., & Williams, G. R. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1106 · Cited by 540 · see citing works
The skeletal consequences of thyrotoxicosis
Nicholls, J. J., Brassill, M. J., Williams, G. R., & Bassett, J. H. D. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0059 · Cited by 138 · see citing works
Acid Suppression Therapy: Where Do We Go from Here?
Scarpignato, C., Pelosini, I., & Di Mario, F. (2006) · Digestive Diseases · doi:10.1159/000091298 · Cited by 119 · see citing works
Hong, A. R., & Kang, H.-C. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2023.1701 · Cited by 15 · see citing works
Li, X., Zhang, T., Zhang, H., Liu, S., & Tian, L. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01819-7 · Cited by 10 · see citing works
Do Premenopausal Hypothyroid Women on Levothyroxine Therapy Need Bone Status Monitoring?
Babu, R. P., Christy, A., Hegde, A., Manjrekar, P., & D'Souza, V. (2015) · Clinical Medicine Insights: Women's Health · doi:10.4137/cmwh.s22114 · Cited by 4 · see citing works
- Authors
- Kanatani, M., Sugimoto, T., Sowa, H., Kobayashi, T., Kanzawa, M., & Chihara, K.
- Affiliations
- Kobe University (JP)
- Corresponding author
- Sugimoto, Toshitsugu
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2004-02-09
- Volume
- 201
- Issue
- 1
- Pages
- 17-25
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2086286088
- Cited by
- 74
- References
- 1
- Citations by year
- 2026: 5 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 4 · 2020: 7 · 2019: 2 · 2018: 3 · 2017: 2 · 2016: 2 · 2015: 3 · 2014: 5 · 2013: 3 · 2012: 5
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Cellular Physiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- thyroid hormones, triiodothyronine, osteoclastogenesis, osteoclast precursors, c-fos, Fra-1, osteoprotegerin, bone loss, osteoclast-like cell formation, mitogen-activated protein kinase
- MeSH terms
- Animals, Carrier Proteins, Cell Differentiation, Glycoproteins, Hematopoietic Stem Cells, Membrane Glycoproteins, Mice, Inbred Strains, Osteoclasts, Receptors, Thyroid Hormone, RNA, Messenger, Spleen, Triiodothyronine, NF-kappa B, Proto-Oncogene Proteins c-fos, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Mitogen-Activated Protein Kinases, p38 Mitogen-Activated Protein Kinases, Mice, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review